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Trauma-induced coagulopathy (TIC) is a clinical scenario spanning the spectrum of 
hypocoagulability to hypercoagulability causing a wide range of complications including 
uncontrolled bleeding and thrombotic disease. TIC is driven by tissue injury [1], where shock 
and hypoperfusion act synergistically to worsen and provoke TIC [2].
Defining the clinical syndrome of TIC has been hampered by the wide variations in 
patient presentation. Severely injured patients manifest diverse phenotypes of TIC spanning 
hypo- and hyper-coagulability and may rapidly progress between phenotypes. The presentation 
is chiefly thought to be a result of the variability of the magnitude and timing of the interaction 
between tissue injury and shock as well as resuscitation practices. Variations in experimental 
measurements such as timing of patient presentation, prior therapy, and timing to blood 
sampling complicate the definition of TIC [3–5].
As a result of the difficulty in defining clinical TIC, the underlying biochemical 
mechanisms of TIC are unclear. Factors contributing to a hypocoaguable state include impaired 
thrombin generation, impaired platelet function, deficient or defective fibrinogen, increased 
fibrinolysis, and endothelial dysfunction, while those contributing to hypercoagulability 
include excessive thrombin generation, endothelial injury, platelet hyperactivity and 
exhaustion, hyperfibrinogenemia, and impaired fibrinolysis [6–16].































































In recent years, multiple definitions of the hemostatic disturbances in trauma have been 
published [17–20]. The unstandardized nomenclature and definitions (ATC; acute traumatic 
coagulopathy, TIC; trauma-induced coagulopathy, ACoTS; acute coagulopathy of trauma-
shock, CoT; coagulopathy of trauma, DIC; disseminated intravascular coagulation, 
endotheliopathy of trauma and hemorrhagic blood failure [21], shock induced endotheliopathy 
(SHINE [5,6]) used to describe these derangements in trauma has led to a considerable degree 
of confusion within the field [22–25].
This communication, from the International Society on Thrombosis and Haemostasis 
(ISTH) Scientific and Standardization Committee (SSC) on fibrinolysis, DIC, and perioperative 
and critical care thrombosis and hemostasis, builds on a previous consideration [26] and 
provides (a) an overview of the current leading theories of the mechanism of TIC, (b) compare 
and contrasts the major overlapping lessons from coagulopathies related to other critical 
illnesses such as sepsis-induced coagulopathy, (c) addresses the critical knowledge gaps in our 
understanding of the pathophysiology of TIC, and (d) defines a new categorization scheme for 
patient groups to better stratify the likely coagulopathic phenotypes and pathophysiology based 
on the patients arrival characteristics. Together, addressing these knowledge gaps may provide 
a roadmap for the development of clinical and point-of-care diagnostic strategies for rapidly 































































and pre-emptively identifying the patient with TIC in order to optimize transfusion and 
resuscitation.
Current understanding of the mechanisms of trauma-induced coagulopathy (TIC)
The CRASH-2 trial demonstrated reduced mortality if tranexamic acid (TXA) is 
administered within 3 hours of the onset of trauma in patients at risk of bleeding, providing 
proof-of-concept for the acute management of coagulopathy in trauma [27]. The key 
coagulation system abnormalities have been attributed to (a) systemic endotheliopathy from 
tissue damage, ischemia, and resuscitation, and (b) the ensuing systemic inflammatory response 
to this injury, which is thought to trigger (c) platelet activation and dysfunction, (d) 
dysregulated coagulation factor activation including in thrombin generation and activated 
protein C, and (e) altered fibrinolysis through the release of tissue-type plasminogen activator 
(t-PA) and/or its inhibitor, plasminogen activator inhibitor-1 (PAI-1).
TIC is driven by two distinct and synergistic insults: hypovolemic shock due to blood 
loss and extensive tissue disruption (Figure 1) [28]. The variables that modify the TIC 
phenotype and course include (a) trauma: injury extent and severity, tissue type injured (head 
[29], orthopaedic [30]), degree of hemorrhagic shock, mechanism of injury (blunt, 































































penetrating/hemorrhagic [31,32]), and time from injury [3,7,20,33–36]; (b) patient factors: age, 
sex, medical comorbidities (cardiovascular disease), concomitant anticoagulant use, presence 
of other toxins including alcohol, heritable differences in baseline coagulation; and (c) 
resuscitation strategies: types of fluids used, the impact of blood components, adjuncts such as 
TXA, and timing of surgical intervention [20,33,36]. The combination of these three variables 
distinguishes TIC from the other acute coagulopathies (i.e. open cardiovascular surgery, liver 
transplantation, postpartum hemorrhage, sepsis, malignancy and autoimmune- and toxin-
mediated coagulopathy) [37–39]. The timing, treatments, and complex interplay of variables 
lead to the various TIC phenotypes. Ongoing dysregulation of coagulation may eventually lead 
to a final common pathway of fulminant coagulation failure and the clinical presentation of 
disseminated intravascular coagulation.
Impaired clot formation is driven by both hypoxia and tissue injury (Figure 2) [28]. 
Proposed mechanisms include the activation of protein C with subsequent deactivation of factor 
(F) V and FVIII, and the release of heparan sulfate and syndecan-1 from the endothelial 
glycocalyx [6,40]. Systemic hyperfibrinolysis is stimulated by hypoxia with endothelial release 
of t-PA, and thrombin generated by activation of coagulation also stimulates t-PA release. 































































Fibrinolysis can be inhibited via the byproducts of tissue injury and activation of platelets 
releasing antifibrinolytic agents such as PAI-1 [28].
Coagulopathic patients can harbor hypofibrinogenemia early after injury, which can be 
a marker of TIC, and is dose-dependently related to shock, injury severity, and mortality [22]. 
Depletion is associated with poor outcomes, an effect which can be reversed with 
supplementation [41]. Low fibrinogen concentrations correlate with increased transfusions, 
ventilator days, and increased early and late mortality [42]. Fibrinogen supplementation 
improves clot initiation and stability [43,44], and may decrease mortality in this group [45]. A 
large observational study in combat-injured patients in Afghanistan suggested that 
supplementation with cryoprecipitate may have independent survival benefit [46]. Current 
European guidelines suggest the early empiric administration of higher concentrations of 
fibrinogen [47], although the benefits are currently being assessed in a number of clinical trials 
[48].
Acute severe injury and haemorrhagic shock cause a complex response of the innate 
immune and inflammatory systems that are tightly coupled with the coagulation system [49]. 
Damage associated molecular pattern proteins (DAMPs) released during tissue injury [50,51] 
and ischemia/reperfusion [52–54] elicit time-dependent changes in coagulation and fibrinolysis 































































that may have common pathways; namely, immediate thrombin generation, t-PA availability, 
and later suppression of fibrinolysis by PAI-1 [55,56]. The behaviour of DAMPs in TIC may 
have similar and related responses after sterile injury to pathogen-associated molecular proteins 
(PAMPs) following infection, a response thought to regulate the severity and progression in 
sepsis and sepsis-induced coagulopathy [57,58].
Comparisons and lessons learned from sepsis-induced coagulopathy (SIC)
As with other coagulopathies, sepsis-induced coagulopathy (SIC) fundamentally differs 
from TIC in its pathophysiology, particularly in the early stage of the diseases. Common 
pathways are activated in both SIC and TIC, and as the dysregulated inflammatory and coagulo-
fibrinolytic responses progress, they may converge on a final pathway of disseminated 
intravascular coagulation (DIC) (Figure 3).
The systemic infections that most commonly trigger SIC are with Staphylococcus 
aureus, Streptococcus pneumonia, Escherichia coli, klebsiella species, and Pseudomonas 
aeruginosa [59–61]. The clinical presentation is that of DIC and is thought to originate from 
loss of localization of clotting factor activation starting in the microvasculature. Patients present 
with either thrombotic or bleeding phenotypes, and the SIC timeline is unclear as the triggering 































































event to coagulopathy is likely distributed over a long phase of infection. The infectious trigger 
causes upregulation of multiple inflammatory biomarkers, leading to widespread fibrin 
deposition and microvascular thrombosis. Fibrinolytic shutdown appears to be a common 
occurrence and similar to late trauma [62]. TXA is not recommended in these patients as their 
recovery is dependent on fibrinolysis to lyse systematic thrombi.
Recent refinement of the diagnosis of SIC has suggested a unique pathophysiologic 
mechanism for sepsis when compared to other coagulopathies. This is of importance since 
refining the diagnosis of SIC allows for early individual treatment based on clinical and 
laboratory presentation [37–39,63]. Recent clarification of the distinction between what has 
classically been called DIC and other forms of acquired coagulopathy in the early stages have 
been noted to advance treatment for those coagulopathies with individualized diagnostic and 
therapeutic options [64].
Proposed stratification of TIC clinical presentation for investigation
The clinical presentation of coagulopathy in TIC can shift between two ends of the 
hemostatic spectrum depending on the time course [8,9], injuries, and prior treatments, where 
one clinical phenotype may be more dominant. This heterogeneous presentation and treatment, 































































complicated by complex and dynamic underlying pathophysiology is the likely source the 
incomplete definitions in the clinical presentation and course of the patient with TIC. We 
propose a clinical stratification to severely injured patients in order to better study and define 
the underlying mechanisms of the clinical phenotypes of TIC.
Currently there is no broadly accepted standard laboratory method to identify and 
prognosticate TIC. In the setting of severe injury and shock, elevated INR has been the most 
robust predictor of mortality, length of ICU stay, and 30-day survival [22,65,66]. These patients 
with elevated INR were more than 4 times likely to die, a finding consistent between military 
and civilian trauma registries. TIC has also been found in patients without severe traumatic 
injuries, although coagulopathy is associated with high ISS. Patients with a base deficit ≤-6 
may also be monitored for underlaying coagulopathy or occult shock [35]. Viscoelastic assays 
such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM) are 
emerging point-of-care tools for providing a global view of hemostasis [67]. The clinical cutoffs 
of these tests are still under investigation [68].
Primary vs. secondary
TIC is a primary endogenous coagulopathy that is at least partly caused by dysregulated 
innate immune inflammatory host responses to trauma and traumatic shock, leading to organ 































































dysfunction and a poor outcome [7]. Anemia, dilution, hypothermia, and acidosis exogenously 
induce secondary coagulopathy, which can modify primary coagulopathy [35].
Early vs. late
In civilian [12] and military [13] settings, uncontrolled hemorrhage is the leading cause 
of preventable death following traumatic injury. Civilian studies reveal that more than 95% of 
deaths from hemorrhage occur within the first 24 hours of the onset of trauma, with a median 
time of approximately 3 hours [12]. The first hours of resuscitation are critical and require 
prompt identification and management to control local and systemic hemostasis. Patients in the 
“late” phase may have ongoing coagulopathy requiring a biochemically driven resuscitation 
strategy following surgical hemostasis.
Enhanced vs. inhibited fibrinolysis
In primary coagulopathy, trauma and traumatic shock give rise to systemic and 
persistent thrombin generation [7,14,18,24,50,56,69] associated with platelet dysfunction 
[15,16] from the early to late phases of trauma. Fibrinolytic systems bring about dynamic two-
phases changes: increased fibrinolysis due to shock-induced t-PA release at an early stage 































































[50,70], and the inhibition of fibrinolysis due to persistent expression of PAI-1 at a later stage 
of trauma [51,71,72]. These imbalances are predictors of mortality in observational studies, and 
importantly, those patients with physiologic levels of fibrinolysis on admission have been 
shown to have the lowest mortality [8–11]. Although depending on the mechanism of injury, 
the type and speed of resuscitative measures imparted, the evolution from hyperfibrinolytic-
type to hypofibrinolytic-type can occur in minutes to hours [10]. Increased fibrinolysis 
accelerates bleeding, thus leading to uncontrolled haemorrhage.
Resuscitation responders versus non-responders
Hemostatic changes in trauma are also modified by resuscitation leading to ischemia-
reperfusion events, which can further derange coagulation. Early TIC is influenced by the 
degree of resuscitation which is a necessity in most cases. Also, therapeutic measures including 
surgical interventions and hemostatic resuscitation as a part of damage control resuscitation 
post injury can modify the late coagulopathy. Sustained systemic inflammatory response 
syndrome associated with the activation of tissue factor-dependent coagulation pathways and 
inhibition of fibrinolysis contributes to organ dysfunction in the late phase of trauma 
[9,10,51,73]. However, when resuscitative measures and the availability/accessibility of 































































allogeneic blood products may be limited (e.g. less-resourced nations or remote locations), the 
TIC spectrum may present a completely different picture, which often leads to early mortality.
Addressing knowledge gaps in the future
Identifying the molecular mechanisms that drive TIC, including the location of where 
coagulation occurs (i.e. intra- versus extra-vascular space segregated by the endothelial layer) 
is crucial for understanding the consequent pathophysiology of coagulopathy [24,26]. In 
addition, this segregation by the endothelial barrier inherently provides control of both 
anticoagulant (e.g. antithrombin and negatively charged glycocalyx, activated protein C) and 
fibrinolytic (e.g. PAI-1, α2-antiplasmin) phenotype. Understanding of the haemostatic effects 
of the damaged/activated endothelium in TIC that consequently leads to pathologic 
coagulopathy is needed to better understand TIC and improve its treatment strategies.
In addition, an agreed upon definition of TIC will subsequently allow for clarification 
and identification of the knowledge gaps that exist. These gaps include identifying: 1) factors 
that regulate progression of TIC to DIC, 2) the differences between primary pathogenic 
mechanisms driving SIC versus TIC, 3) the significance of dysregulated fibrinolysis and 































































anticoagulation in TIC, 4) the distinguishing characteristics of early and late phenotypes in TIC, 
5) the role of platelet dysfunction in SIC and TIC, and 6) the diagnostic criteria of SIC and TIC.
Summary
TIC is a clinical disease process that encapsulates multiple defects to major systems in 
hemostasis in the acutely severely injured patient. Patients at various stages can present on a 
spectrum between bleeding and thromboembolism, with untreated TIC leading eventually to a 
picture of fulminant DIC. Heterogeneity in patient injury factors complicate the definition of 
the clinical presentation of TIC, study of the underlying pathophysiology of TIC, and devising 
optimal strategies for treating the primary defects in TIC. To decrease the heterogeneity, this 
communication proposes that the study of trauma patients suffering from TIC be assessed on 
the following factors: i) primary or secondary coagulopathy based on the pathophysiology, ii) 
early or late coagulopathy based on the timing, iii) increased or inhibited fibrinolysis 
phenotypes based on the dynamics of fibrinolysis, and iv) resuscitated or non-resuscitated state 
based on the rescue measures provided. If adopted, these steps could dramatically improve 
patient care in the acute stages of trauma and facilitate examination of the underlying 
pathophysiological mechanisms.
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Figure Legends
Figure 1. Mechanisms of impaired clot formation in TIC. Impaired clot formation is driven 
by both hypoxia and tissue injury. Proposed mechanisms include the generation of activated 
protein C with subsequent deactivation of factors Va and VIIIa, and the release of heparan 
sulfate from the endothelial glycocalyx. Adapted from Moore et al. [28]
Figure 2. Factors regulating fibrinolysis in TIC. Systemic hyperfibrinolysis is stimulated by 
hypoxia with endothelial release of t-PA that activates plasminogen. On the other hand, 
fibrinolysis is inhibited via the by-products of tissue injury and activation of platelets releasing 
antifibrinolytic agents. Adapted from Moore et al. [28]
Figure 3. The overlap of SIC and TIC. Adapted from Iba et al. [37]
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